Ceftru-CV 100 Tablet
Cefpodoxime 100 mg + Clavulanic Acid 62.5 mg Tablets
| Composition | Cefpodoxime 100 mg + Clavulanic Acid 62.5 mg |
|---|---|
| Dosage Form | Tablet |
| Pack Type | Alu-Alu Blister |
| Pack Size | 10 x 10 Tablets |
| MRP | ₹ 1440 |
| Therapy | Antibiotic + G.P. + Orthopaedics — Third-Gen Cephalosporin + Beta-Lactamase Inhibitor |
| Storage | Store below 30 °C in a dry place, protected from light and moisture. |
📱 WhatsApp Enquiry📞 Call: +919041677932
About Ceftru-CV 100 Tablet
Ceftru-CV 100 Tablet combines Cefpodoxime 100 mg with Clavulanic Acid 62.5 mg in a solid-dosage form for adolescents and adults requiring beta-lactamase-protected cefpodoxime therapy at the lower dose level — suited to less severe but resistant infections.
The combination is widely used for sinusitis, otitis media in adolescents, lower respiratory tract infections and skin infections where beta-lactamase-producing organisms are suspected.
Ceftru-CV 100 is manufactured by Trumac Healthcare under WHO-GMP conditions. Available for monopoly-based PCD pharma franchise and third-party manufacturing.
Indications
- Sinusitis with beta-lactamase prevalence
- Otitis media in adolescents
- Lower respiratory tract infections
- Skin and soft-tissue infections
- Uncomplicated UTI with prior antibiotic exposure
Mechanism of Action
Cefpodoxime Proxetil is an oral third-generation cephalosporin prodrug that is hydrolysed in intestinal mucosa to active cefpodoxime. It binds penicillin-binding proteins, inhibiting peptidoglycan cross-linking. Broad spectrum covering gram-negative (H. influenzae, M. catarrhalis, E. coli, Klebsiella) and selected gram-positive (streptococci, MSSA) organisms — including many beta-lactamase-producing strains. Clavulanate inhibits beta-lactamases.
Dosage & Administration
Adolescents and adults: 1 tablet twice daily for 7–10 days with food.
Side Effects
Diarrhoea, nausea, vomiting, mild rash, headache. Rare: pseudomembranous colitis, anaphylaxis, severe skin reactions. Cross-reactivity with penicillin allergy (~5–10%). Increased GI upset due to clavulanate.
Contraindications & Precautions
Hypersensitivity to cephalosporins. Severe penicillin allergy. Caution in renal impairment (dose adjustment). Caution in GI disease. History of cholestatic jaundice with clavulanate.
Storage
Store below 30 °C in a dry place, protected from light and moisture.
Ceftru-CV 100 Tablet is available for monopoly-based PCD pharma franchise across India and for third-party manufacturing under your brand. WHO-GMP certified, with full visual-aid and promotional support. Become a Trumac franchise partner →
Frequently Asked Questions
What is Ceftru-CV 100 used for?
Ceftru-CV 100 contains Cefpodoxime 100 mg + Clavulanic Acid Tablet and is used for bacterial infections — UTI, ENT, respiratory tract, skin/soft-tissue infections in the appropriate age group.
How long is the course?
Typical course is 5–10 days; longer in complicated infections. Always complete the prescribed course.
Is Ceftru-CV 100 available for PCD pharma franchise?
Yes, Trumac Healthcare offers Ceftru-CV 100 on monopoly-based PCD pharma franchise and for third-party manufacturing.
How should Ceftru-CV 100 be stored?
Store below 30 °C in a dry place, protected from light and moisture.
Is Ceftru-CV 100 WHO-GMP certified?
Yes, manufactured in WHO-GMP and DCGI-compliant facilities.
Related Products
- Ceftru-CV 200 Tablet — Cefpodoxime 200 mg + Clavulanic Acid 125 mg
- Ceftru-CV Dry Syrup — Cefpodoxime 50 mg + Clavulanic Acid 31.25 mg per 5 ml (Dry Syrup)
- Ceftru-100 DT Tablet — Cefpodoxime Proxetil 100 mg